Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tizanidine hydrochloride
Drug ID BADD_D02231
Description Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
Indications and Usage Tizanidine is indicated for the relief of muscle spasticity, which can interfere with daily activities. The general recommendation is to reserve tizanidine use for periods of time when there is a particular need for relief, as it has a short duration of action [FDA label, F4471].
Marketing Status approved; investigational
ATC Code M03BX02
DrugBank ID DB00697
KEGG ID D00776
MeSH ID C023754
PubChem ID 114869
TTD Drug ID D01MDT
NDC Product Code 75834-209; 51927-0020; 42291-811; 46708-492; 50742-225; 42291-810; 59651-314; 59651-315; 62332-493; 63629-2466; 72241-043; 46708-493; 59651-316; 60505-2650; 61919-196; 63629-2494; 71209-064; 71209-066; 63629-2467; 63629-5139; 70771-1069; 71209-065; 0591-2789; 72888-002; 55700-865; 60505-2648; 62332-492; 0591-2788; 71335-9743; 71610-114; 75834-208; 55700-999; 60505-2649; 70515-606; 70710-1112; 70771-1067; 72241-041; 49999-347; 70710-1113; 70771-1068; 71335-1698; 38779-2351; 65015-777; 42291-812; 46708-491; 50742-226; 62332-491; 70515-604; 71335-0317; 0591-2790; 75834-207; 66022-0202; 45865-954; 68788-8478; 70515-602; 70710-1111; 72888-003; 53747-003; 50742-224; 70515-594; 72241-042; 72888-001; 55111-020; 63278-0489
UNII B53E3NMY5C
Synonyms tizanidine | 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole | Zanaflex | tizanidine hydrochloride | tizanidine monohydrochloride | DS 103-282 | Sirdalud
Chemical Information
Molecular Formula C9H9Cl2N5S
CAS Registry Number 64461-82-1
SMILES C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Abscess11.01.08.001--Not Available
Acne23.02.01.001--Not Available
Adrenal insufficiency14.11.01.004; 05.01.02.001--
Agitation19.06.02.001; 17.02.05.012--
Alanine aminotransferase increased13.03.04.005--
Albuminuria20.02.01.001--Not Available
Alopecia23.02.02.001--
Amblyopia06.02.01.001--Not Available
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Angina pectoris24.04.04.002; 02.02.02.002--
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.010--Not Available
Back pain15.03.04.005--
Blood pressure decreased13.14.03.002--Not Available
Bradycardia02.03.02.002--Not Available
Bronchitis11.01.09.001; 22.07.01.001--
Bursitis12.04.03.010; 15.04.01.001--Not Available
Cardiac failure02.05.01.001--
Cellulitis23.11.02.004; 11.02.01.001--Not Available
Cholelithiasis09.03.01.002--Not Available
Congenital anomaly03.02.01.001--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages